Featured Video Play Icon

New School in Hyderabad

We are proud and happy to announce that our construction of a new school building which is located close to our facility in Hyderabad, India, has now been completed. It was officially inaugurated by our AET Laboratories team together with the Hamburg management, Oliver Schrader and Dr. Kristian Ruepp.

As a value-driven healthcare company, dedicated to improve the life of patients worldwide, we believe that it´s our responsibility to care about the environment and society – especially in the countries in which we operate. With this initiative we give children from the neighborhood the chance to have a better future through better education.

The school in Gaddapotharam Village will initially accommodate more than 200 students from class 1 to 5. The new school building is on par with the corporate schools in the city in terms of infrastructure and equipment, according to government officials at the Ministry of Education. The event was covered by the local / national media and grabbed the attention of the people for the valued contribution by Tiefenbacher Group to the society.

For Tiefenbacher Group it is a rewarding experience to give back to the community. Our culture of caring is fundamental to achieving our goal of significantly improving the daily lives of people around the world. In the future we will continue promoting education and health in various community engagement projects that are in line with our values and beliefs.

AET Tiefenbacher Pharmaceuticals, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).  

For more information about our finished dosage forms and healthcare solutions, please contact AET Tiefenbacher Pharmaceuticals: info@aet.eu or please visit us on:www.aet.eu 

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963 
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. Our purpose is to improve people’s lives by creating pharmaceuticals more affordable, more available, and better than before.Further information about our better healthcare solutions and in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) can be found on www.tiefenbacher.com or you can contact us info@tiefenbacher.com  


Featured Video Play Icon

NEW WEBSITE ONLINE!

We are happy to announce that we have launched a new web page for OYSTA – an innovative healthcare brand which we have developed together with our partner Ondosis.
With OYSTA, we aim to revolutionize the way how patients take their medicines by combining pharmaceuticals with e-health technology to enable intuitive, precise, and flexible dosing.

About Tiefenbacher Group– Pioneering Healthcare since 1963 
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines  around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our goal is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.  

For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email atinfo@tiefenbacher.com 


Successful Approval of manufacturing and laboratory facilities by Saudi Food and Drug Authority

New site approval! We are happy to announce that our manufacturing and laboratory facilities for oral solids at AET Laboratories in Hyderabad (India) have been successfully registered by the Saudi Food and Drug Authority.

The registration is a great door opener for the full GCC region. It is an important addition to our existing European and international certifications (like the US FDA approval) and follows Tiefenbacher Group´s strategy to make our high-quality pharmaceuticals better available worldwide!

About Tiefenbacher Group– Pioneering Healthcare since 1963 
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines  around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our goal is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.  

For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email atinfo@tiefenbacher.com 


TIEFENBACHER GROUP IS COMMITTED TO BECOMING CLIMATE NEUTRAL

We are pleased to share that TIEFENBACHER GROUP is committed to becoming climate neutral by the end of 2025*. As a value-driven healthcare company, dedicated to improving the life of patients worldwide, we recognize the importance of taking action to address the urgent climate crisis we face today. To achieve this goal, we are implementing a comprehensive sustainability strategy that includes the following measures, among others:

As our biggest driver of the carbon footprint is energy consumption, large-scale solar panels will be installed on our manufacturing facilities in Cyprus and India. Any electricity that cannot be produced in-house and must be purchased will be purely green electricity. In addition, we are implementing energy saving and efficiency measures – especially at our production sites. Furthermore, all company vehicles will be exclusively electric in the future. With these measures, we will already achieve a great interim goal: reducing our emissions by 80% by January 2024.

We believe that this is not only the right thing to do for the planet but also the right thing to do for our business. Being commercially successful and operating responsibly by becoming climate neutral is how we generate sustainable returns. We look forward to sharing more updates on our progress towards this important goal in the coming months and years.

*Scope 1 and 2 according to GHG as well as business travel and employee commuting

About Tiefenbacher Group– Pioneering Healthcare since 1963 
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines  around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our goal is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.  

For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email atinfo@tiefenbacher.com 


Featured Video Play Icon

RENOVATING HEADQUARTERS IN HAMBURG

Did you know that Tiefenbacher Group is currently renovating its headquarters in Hamburg, Germany? We are excited to share the first results of the restructuring and are pleased to bring the first changes to life.

The newly designed building will be a modern and innovative workspace that reflects our culture of entrepreneurship, professional excellence, and openness. The open-floor concept promotes creativity, collaboration, and teamwork among our employees. We believe that the new space, right on the banks of the river Elbe, provides a great working environment that supports the growth and wellbeing of our employees at the same time.

Watch our short video to see the first changes. We´ll keep you posted on the progress and look forward to welcoming you to our new office space soon!

About Tiefenbacher Group– Pioneering Healthcare since 1963 
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines  around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our goal is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.  

For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email atinfo@tiefenbacher.com 


Featured Video Play Icon

TIEFENBACHER GROUP AT DCAT 2023 – THANKS FOR MEETING US IN NEW YORK CITY!

DCAT week – one of the world´s most important pharma events – has just come to an end. It was four very successful and inspiring days for TIEFENBACHER GROUP in New York City. What a pleasure to present our latest product portfolio and innovations and to connect with existing and potential new partners. Check out our short video to get some impressions!

About Tiefenbacher Group– Pioneering Healthcare since 1963 
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines  around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our goal is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.  

For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email atinfo@tiefenbacher.com 


NEW MARKET LAUNCH: TIEFENBACHER PHARMACEUTICALS SUCCESSFULLY LAUNCHES THE ANTIHISTAMINE BILASTINE FOR A MARKET ENTRY AS OVER-THE-COUNTER (OTC) MEDICINE IN GERMANY

As the allergy season is starting, we at TIEFENBACHER PHARMACEUTICALS are thrilled to announce that we have successfully prepared the launch of the antihistamine Bilastine for a market entry as Over-the-counter (OTC) medicine in Germany.

Bilastine is an innovative anti-allergy medicine for patients suffering from allergic symptoms, such as hay fever and urticaria. It belongs to the non-sedating second-generation antihistamines. The 20 mg tablets have been developed in TIEFENBACHER GROUP´s own laboratories and will be marketed by our partner, a well-known international pharmaceutical company.

With this market entry we enable patients in Germany a better access to an important medicine which is currently the only product of this type available in pharmacies without a prescription needed. Further launches in European markets are planned soon.

AET Tiefenbacher Pharmaceuticals, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).  

For more information about our finished dosage forms and healthcare solutions, please contact AET Tiefenbacher Pharmaceuticals: info@aet.eu or please visit us on:www.aet.eu 

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963 
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. Our purpose is to improve people’s lives by creating pharmaceuticals more affordable, more available, and better than before.Further information about our better healthcare solutions and in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) can be found on www.tiefenbacher.com or you can contact us info@tiefenbacher.com  


TIEFENBACHER GROUPS MANUFACTURING SITES HAVE BEEN SUCCESSFULLY REGISTERED BY THE UNITED ARAB EMIRATES MINISTRY OF HEALTH

We are excited to announce that our two manufacturing sites at AET Laboratories in Hyderabad (India) and at Delorbis in Lefkosia (Cyprus) have been successfully registered by the United Arab Emirates Ministry of Health! The approvals are based on our existing European and international certifications and follow Tiefenbacher Group´s strategy to make our high-quality pharmaceuticals better available worldwide!

About Tiefenbacher Group– Pioneering Healthcare since 1963 
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines  around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our goal is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.  

For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email atinfo@tiefenbacher.com 


World Cancer Day 2023

We are approaching World Cancer Day 2023. Cancer has a global impact of around 20 million new cases each year, remaining a major public health challenge. In the fight against this disease, we at TIEFENBACHER GROUP are committed to deliver better affordable medicines for cancer patients around the world.

Hereby we are always aiming to improve patients’ lives by developing added value medicines with a better posology, additional strengths, suitable fixed dosage combinations, or personalized therapies by combining medicines with smart e-health solutions – just to name a few of our differentiated and innovative product solutions.

TIEFENBACHER PHARMACEUTICALS (FDF business unit of TIEFENBACHER GROUP) has already 25 leading highly potent cancer drugs in its launch pipeline which are planned to be developed and manufactured in our new state-of-the-art high potent facilities in Hyderabad, India.

AET Tiefenbacher Pharmaceuticals, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).  

For more information about our finished dosage forms and healthcare solutions, please contact AET Tiefenbacher Pharmaceuticals: info@aet.eu or please visit us on:www.aet.eu 

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963 
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. Our purpose is to improve people’s lives by creating pharmaceuticals more affordable, more available, and better than before.Further information about our better healthcare solutions and in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) can be found on www.tiefenbacher.com or you can contact us info@tiefenbacher.com  


Featured Video Play Icon

TIEFENBACHER GROUP wishes a happy and healthy Chinese New Year 2023!

We at TIEFENBACHER GROUP appreciate the diversity of our colleagues very much and are happy to celebrate their local traditions together. In the culture of our Chinese partners and colleagues, a certain animal of the Chinese zodiac is assigned to each year. This year is the year of the rabbit. Watch our colleague Danna from China sharing short Lunar New Year greetings in her local language!

About Tiefenbacher Group– Pioneering Healthcare since 1963 
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines  around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our goal is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.  

For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email atinfo@tiefenbacher.com